109 related articles for article (PubMed ID: 21078557)
1. Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.
Yang JS; Chun K; Park JE; Cho M; Seo J; Song D; Yoon H; Park CH; Joe BY; Choi JH; Kim MH; Han G
Bioorg Med Chem; 2010 Dec; 18(24):8618-29. PubMed ID: 21078557
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
3. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
[TBL] [Abstract][Full Text] [Related]
4. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.
Gilmore JL; King BW; Asakawa N; Harrison K; Tebben A; Sheppeck JE; Liu RQ; Covington M; Duan JJ
Bioorg Med Chem Lett; 2007 Aug; 17(16):4678-82. PubMed ID: 17576061
[TBL] [Abstract][Full Text] [Related]
6. Anthranilate derivatives as TACE inhibitors: docking based CoMFA and CoMSIA analyses.
Bahia MS; Gunda SK; Gade SR; Mahmood S; Muttineni R; Silakari O
J Mol Model; 2011 Jan; 17(1):9-19. PubMed ID: 20349256
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
Mazzola RD; Zhu Z; Sinning L; McKittrick B; Lavey B; Spitler J; Kozlowski J; Neng-Yang S; Zhou G; Guo Z; Orth P; Madison V; Sun J; Lundell D; Niu X
Bioorg Med Chem Lett; 2008 Nov; 18(21):5809-14. PubMed ID: 18835710
[TBL] [Abstract][Full Text] [Related]
8. Novel methods and strategies in the discovery of TACE inhibitors.
Murumkar PR; Giridhar R; Yadav MR
Expert Opin Drug Discov; 2013 Feb; 8(2):157-81. PubMed ID: 23231541
[TBL] [Abstract][Full Text] [Related]
9. Biaryl substituted hydantoin compounds as TACE inhibitors.
Yu W; Tong L; Kim SH; Wong MK; Chen L; Yang DY; Shankar BB; Lavey BJ; Zhou G; Kosinski A; Rizvi R; Li D; Feltz RJ; Piwinski JJ; Rosner KE; Shih NY; Siddiqui MA; Guo Z; Orth P; Shah H; Sun J; Umland S; Lundell DJ; Niu X; Kozlowski JA
Bioorg Med Chem Lett; 2010 Sep; 20(17):5286-9. PubMed ID: 20663669
[TBL] [Abstract][Full Text] [Related]
10. Conversion of potent MMP inhibitors into selective TACE inhibitors.
Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
[TBL] [Abstract][Full Text] [Related]
11. Novel TACE inhibitors in drug discovery: a review of patented compounds.
Murumkar PR; DasGupta S; Chandani SR; Giridhar R; Yadav MR
Expert Opin Ther Pat; 2010 Jan; 20(1):31-57. PubMed ID: 20021284
[TBL] [Abstract][Full Text] [Related]
12. Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
Ott GR; Asakawa N; Lu Z; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Traskos JM; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2008 Jan; 18(2):694-9. PubMed ID: 18061445
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
[TBL] [Abstract][Full Text] [Related]
14. Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.
Murumkar PR; Zambre VP; Yadav MR
J Comput Aided Mol Des; 2010 Feb; 24(2):143-56. PubMed ID: 20179991
[TBL] [Abstract][Full Text] [Related]
15. 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.
Dai C; Li D; Popovici-Muller J; Zhao L; Girijavallabhan VM; Rosner KE; Lavey BJ; Rizvi R; Shankar BB; Wong MK; Guo Z; Orth P; Strickland CO; Sun J; Niu X; Chen S; Kozlowski JA; Lundell DJ; Piwinski JJ; Shih NY; Siddiqui MA
Bioorg Med Chem Lett; 2011 May; 21(10):3172-6. PubMed ID: 21458257
[TBL] [Abstract][Full Text] [Related]
16. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
Wu D; Gu Q; Zhao N; Xia F; Li Z
J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
[TBL] [Abstract][Full Text] [Related]
17. Current perspective of TACE inhibitors: a review.
DasGupta S; Murumkar PR; Giridhar R; Yadav MR
Bioorg Med Chem; 2009 Jan; 17(2):444-59. PubMed ID: 19095454
[TBL] [Abstract][Full Text] [Related]
18. Prediction of novel and selective TNF-alpha converting enzyme (TACE) inhibitors and characterization of correlative molecular descriptors by machine learning approaches.
Cong Y; Yang XG; Lv W; Xue Y
J Mol Graph Model; 2009 Oct; 28(3):236-44. PubMed ID: 19729328
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
[TBL] [Abstract][Full Text] [Related]
20. Discovery and SAR of hydantoin TACE inhibitors.
Yu W; Guo Z; Orth P; Madison V; Chen L; Dai C; Feltz RJ; Girijavallabhan VM; Kim SH; Kozlowski JA; Lavey BJ; Li D; Lundell D; Niu X; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Sun J; Tong L; Umland S; Wong MK; Yang DY; Zhou G
Bioorg Med Chem Lett; 2010 Mar; 20(6):1877-80. PubMed ID: 20172725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
